Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
09/2007
09/07/2007WO2007099069A1 Method of treating inflammatory skin diseases using tropisetron, and pharmaceutical compositions thereof
09/07/2007WO2007098968A1 Triggered release of liposome contents
09/07/2007WO2007098967A2 Imidazole compounds having pharmaceutical activity towards the sigma receptor
09/07/2007WO2007098963A1 Sigma receptor inhibitors
09/07/2007WO2007098962A1 Sigma receptor compounds
09/07/2007WO2007098961A1 4, 5, 6,7-tetrahydrobenzo[b]thiophene derivatives and their use as sigma receptor ligands
09/07/2007WO2007098953A1 Pyrazole derivatives as sigma receptor inhibitors
09/07/2007WO2007098939A1 Use of compounds binding to the sigma receptor for the treatment of metabolic syndrome
09/07/2007WO2007098868A1 Use of moxifloxacin in combination with cefixime for treatment of infectious diseases caused by gram-positive and gram-negative pathogens
09/07/2007WO2007098860A1 New morphine compounds for pharmaceutical compositions
09/07/2007WO2007098835A1 Amino pyrymidine derivatives
09/07/2007WO2007098828A1 Contraceptive
09/07/2007WO2007098770A1 Aryl/alkyl vinyl sulfone hyaluronic acid derivatives
09/07/2007WO2007098719A1 Use of ck2 inhibitor for the treatment and chemosensibilization of refractory tumors to anticancer drugs
09/07/2007WO2007098681A1 Use of a monoterpene in manufacturing medicaments for treating diabetes mellitus
09/07/2007WO2007098680A1 The uses of d-limonene, plant or valatile oil thereof containing d-limonene in manufacturing medicaments for preventing and treating diabetes
09/07/2007WO2007098644A1 Benzopyran compounds and their preparation method and their usage
09/07/2007WO2007098607A1 Methods and compositions to treat and detect misfolded-sod1 mediated diseases
09/07/2007WO2007098604A1 Preventing il-2 mediated inflammation in epithelial cells
09/07/2007WO2007098597A1 Glycosidase inhibitors and methods of synthesizing same
09/07/2007WO2007098588A1 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
09/07/2007WO2007098520A1 Process for the manufacture of a composition containing at least one xanthophyll
09/07/2007WO2007084857A3 Methods and compositions for treating cell proliferative disorders
09/07/2007WO2007084535A3 Neuronal nicotinic receptor ligands and their use
09/07/2007WO2007084532A3 Combination therapy with parp inhibitors
09/07/2007WO2007084290A3 Compositions of an anticonvulsant and psychotherapeutic and methods of using the same for reversing weight gain
09/07/2007WO2007082978B1 Taxane pharmaceutical formulation, solid taxane composition, method for preparing the solid taxane composition, composition for solubilising said solid taxane composition and set of elements (kit) for the injectable taxane formulation
09/07/2007WO2007082909A3 Method for treating huntington's disease by inhibiting dephosphorylation of huntingtin at s421
09/07/2007WO2007081879A3 Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
09/07/2007WO2007079914A3 Combination of triazine derivatives and insulin secretion stimulators
09/07/2007WO2007079317A3 Use of sedative hypnotics for treating obesity or maintaining weight loss
09/07/2007WO2007077329A3 New association of a sinus current if inhibitor and a calcic inhibitor, and pharmaceutical compositions containing the same
09/07/2007WO2007076601B1 Imaging of d2high receptors using radiolabelled (-)- quinpirole and analogs thereof
09/07/2007WO2007075688A3 Substituted aniline derivatives useful as histamine h3 antagonists
09/07/2007WO2007074475A3 Novel polymorphic forms of ibandronate
09/07/2007WO2007073472A3 Tripodal ligands with the coordinating motifs k2-bh2 or k3-bh3 relevant for biomedical applications of organometallic complexes
09/07/2007WO2007073398A3 Compositions and methods for the sustained release of beta-alanine
09/07/2007WO2007071733A3 Use of dha, epa or dha-derived epa for treating a pathology associated with cellular oxidative damage
09/07/2007WO2007071721A3 Ginger extract for inhibiting human drug transporters
09/07/2007WO2007071708A3 Ginger fraction for inhibiting human cyp enzymes
09/07/2007WO2007070816A3 Thiophene derivatives as factor xia inhibitors
09/07/2007WO2007068615A3 Hcv prodrug formulation
09/07/2007WO2007068434A3 Medicament based on a monoester of steroids with long chain fatty acids
09/07/2007WO2007066200A3 Inhibitors of cysteine proteases, the pharmaceutical compositions thereof and their therapeutic applications
09/07/2007WO2007065713A8 Use of 8-alpha-ergolines for the treatment of traumatic brain disorders
09/07/2007WO2007065638A3 Matrix-controlled transdermal system comprising salts of ace inhibitor dicarboxylic acids
09/07/2007WO2007064304A8 Biocompatible composition and uses thereof
09/07/2007WO2007063509A8 Phosphocreatine complexes
09/07/2007WO2007062058A3 Carbamate compounds as 5-ht4 receptor agonists
09/07/2007WO2007060240A3 Method for demonstrating presence or absence of markers (eef1a1 or mark3 )associated with the presence and/or the chemosensitivity of tumors
09/07/2007WO2007060144A3 Novel quinoxaline derivatives and their medical use
09/07/2007WO2007058991A3 Mutations and polymorphisms of c-abl
09/07/2007WO2007058989A3 Quinazolines useful as modulators of voltage gated ion channels
09/07/2007WO2007057849A3 2,3,4,5-tetrahydroxy-6-sulfooxyhexanoic acid and its metal salts for medical use
09/07/2007WO2007056244A3 Methods of using saha and erlotinib for treating cancer
09/07/2007WO2007056056A3 Mitotic kinesin inhibitors
09/07/2007WO2007055563A3 Pharmaceutical combinations comprising testosterone in the treatment of female sexual dysfunction
09/07/2007WO2007054514A3 Use of pde iii inhibitors or calcium sensitizers for the treatment of asymptomatic (occult) heart failure
09/07/2007WO2007052125A3 Solid oral pharmaceutical compositions for once daily dosing containing pregabalin, a matrix forming agent and a swelling agent
09/07/2007WO2007050543A3 Topical pharmaceutical foam composition
09/07/2007WO2007044976A3 Improved testosterone gel and method of use
09/07/2007WO2007042827A3 Treatment and diagnosis of obligate intracellular pathogens
09/07/2007WO2007039177A3 Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals
09/07/2007WO2007035957A3 Methods for treating viral infections using polyamine analogs
09/07/2007WO2007031878A3 Methods of treating nervous disorders
09/07/2007WO2007029156A3 Isoindoledione derivatives as adrenergic receptor antagonists
09/07/2007WO2007028978A3 Ramipril formulation
09/07/2007WO2007023243A3 Cleavage of antifolate compounds
09/07/2007WO2007022173A3 Crystalline forms fenoldopam mesylate
09/07/2007WO2007016450A3 Methods for treating or preventing reactivation of a latent herpesvirus infection
09/07/2007WO2007011878A3 Beta-lactamyl phenylalanine, cysteine, and serine vasopressin antagonists
09/07/2007WO2007011760A3 Inhibitors of mitotic kinesin
09/07/2007WO2007009963A1 Substituted amides, their preparation and their use as pharmaceuticals
09/07/2007WO2007009539A3 Use of inhibitors of histone deacetylases in combination with nsaid for the therapy of cancer and/or inflammatory diseases
09/07/2007WO2006124544A3 Use of tyrosine kinase inhibitors in the treatment of metabolic disorders
09/07/2007WO2006122309B1 Stable lyophilized anthracycline glycosides
09/07/2007WO2006110679A3 Thread sealants with engineered fibers
09/07/2007WO2006097472A3 Novel inhibitors of glutathione-s-transferase
09/07/2007WO2006089708A8 Crystalline forms of (1rs,3rs,6rs)-6-dimethvlaminomethvl-1-(3-methoxv- phenyl)cyclohexane-1 ,3-diol hydrochloride
09/07/2007WO2006084912A8 Device method, and use for treatment of neuropathy involving nitric oxide
09/07/2007WO2006079217A8 Treatment of degenerative diseases with the x-linked inhibitor of apoptosis
09/07/2007WO2006041888A3 Substituted aryl or heteroarylsulfonylbutanamides for use as anti-inflammatory agents
09/07/2007WO2002075302A8 Method for therapeutically treating a clinically recognized form of cardiopathology in a living mammal
09/07/2007CA2679271A1 Glycosidase inhibitors and methods of synthesizing same
09/07/2007CA2645123A1 Use of dha and ara in the preparation of a composition for regulating gene expression
09/07/2007CA2644933A1 Combinations comprising a histone deacetylase inhibiting agent and a nuclear hormone receptor ligand for treating cardiovascular conditions
09/07/2007CA2644810A1 Prophylactic or therapeutic agents for allergic ophthalmic diseases or allergic nasal diseases, comprising tricyclic triazolobenzazepine derivative
09/07/2007CA2644809A1 17 .beta. hsd type 5 inhibitor
09/07/2007CA2644594A1 Diagnosis and treatment of prostate cancer
09/07/2007CA2644578A1 Novel dual action receptors antagonists (dara) at the ati and eta receptors
09/07/2007CA2644570A1 Hydroxylated long-chain resveratrol derivatives useful as neurotrophic agents
09/07/2007CA2644566A1 Cancer treatments
09/07/2007CA2644513A1 Preventing il-2 mediated inflammation in epithelial cells
09/07/2007CA2644458A1 Method of treating inflammatory skin diseases using tropisetron, and pharmaceutical compositions thereof
09/07/2007CA2644136A1 Cancer treatment with gamma-secretase inhibitors
09/07/2007CA2644069A1 Therapeutic piperazines as pde4 inhibitors
09/07/2007CA2644068A1 Therapeutic compounds
09/07/2007CA2644046A1 Metabolic regulators and uses thereof
09/07/2007CA2643973A1 Pharmaceutical composition containing butea isoflavones for the prevention /treatment of bone disorders and a process for the preparation thereof
09/07/2007CA2643838A1 Pyrimidinyl sulfonamide compounds which inhibit leukocyte adhesion mediated by vla-4